pimobendan has been researched along with Cardiac Arrest, Sudden in 5 studies
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with chronic congestive heart failure, pimobendan produces a dose-dependent and prolonged decrease in pulmonary capillary wedge pressure and an increase in cardiac output." | 6.38 | Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. ( Hagemeijer, F, 1993) |
| "Pimobendan was beneficial regardless of HF stage, but increased sudden cardiac death in end-stage HF with extensive remodelling of Ca(2+) handling." | 5.42 | Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. ( Arioka, M; Kurebayashi, N; Li, L; Morimoto, S; Murayama, T; Nonaka, M; Sasaguri, T; Takahashi-Yanaga, F; Wang, YY; Yoshihara, T, 2015) |
| "This retrospective study reports the survival time [onset of congestive heart failure (CHF) to death from any cause] of 21 dogs with mitral regurgitation (MR) and CHF treated with a combination of furosemide, angiotensin-converting enzyme inhibitor (ACEI, benazepril, or enalapril), pimobendan, spironolactone, and amlodipine." | 3.77 | Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases. ( de Madron, E; King, JN; Strehlau, G; White, RV, 2011) |
| "In patients with chronic congestive heart failure, pimobendan produces a dose-dependent and prolonged decrease in pulmonary capillary wedge pressure and an increase in cardiac output." | 2.38 | Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. ( Hagemeijer, F, 1993) |
| "Pimobendan was beneficial regardless of HF stage, but increased sudden cardiac death in end-stage HF with extensive remodelling of Ca(2+) handling." | 1.42 | Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. ( Arioka, M; Kurebayashi, N; Li, L; Morimoto, S; Murayama, T; Nonaka, M; Sasaguri, T; Takahashi-Yanaga, F; Wang, YY; Yoshihara, T, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nonaka, M | 1 |
| Morimoto, S | 2 |
| Murayama, T | 1 |
| Kurebayashi, N | 1 |
| Li, L | 1 |
| Wang, YY | 2 |
| Arioka, M | 1 |
| Yoshihara, T | 1 |
| Takahashi-Yanaga, F | 2 |
| Sasaguri, T | 2 |
| de Madron, E | 1 |
| King, JN | 1 |
| Strehlau, G | 1 |
| White, RV | 1 |
| Du, CK | 1 |
| Nishii, K | 1 |
| Minakami, R | 1 |
| Ohta, M | 1 |
| Tadano, N | 1 |
| Lu, QW | 1 |
| Zhan, DY | 1 |
| Mochizuki, M | 1 |
| Kita, S | 1 |
| Miwa, Y | 1 |
| Iwamoto, T | 1 |
| Ohtsuki, I | 1 |
| Solaro, RJ | 1 |
| Hagemeijer, F | 1 |
1 review available for pimobendan and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure.
Topics: Animals; Calcium; Death, Sudden, Cardiac; Heart Failure; Hemodynamics; Humans; Myocardial Contractio | 1993 |
4 other studies available for pimobendan and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure.
Topics: Animals; Calcium Channels, L-Type; Calcium Signaling; Cardiomyopathy, Dilated; Cardiotonic Agents; D | 2015 |
Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cardiotonic Agents; Death, Sudden, | 2011 |
Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation.
Topics: Amino Acid Sequence; Animals; Calcium; Cardiomyopathy, Dilated; Cardiotonic Agents; Cell Membrane Pe | 2007 |
Translational medicine with a capital T, troponin T, that is.
Topics: Amino Acid Sequence; Animals; Calcium; Cardiomyopathy, Dilated; Cardiotonic Agents; Cell Membrane Pe | 2007 |